Intraviteral Conbercept Treatment For Choroidal Neovascularization

Objective: To observe the efficacy and safety of intravitreal injection of Conbercept fortreatment of choroidal neovascularization(CNV)．Methods: Controlled study of clinical cases before and after treatment.We retrospectivelyanalysis35patients(with36eyes)visiting to our hospital from April2014to March2015.They were checked by Vision，Intraocular Pressure，Slit lamp microscope，90D Slitlamp front mirror,Color fondus photography，Optic coherence tomography(OCT),Fundusfluorescein angiography(FFA), or Indocyanine green angiography(ICGA),and werediagnosed as choroidal neovascularization(CNV). They have no serious cardiovascular andsystemic disease，no operation contraindication.Adoption of international standards on thevision chart lines of best corrected visual acuity (BCVA) and optical coherence tomography(OCT) examination center macular retinal thickness (CRT).For the convenience of statisticalanalysis, vision converted to minimum resolution Angle of logarithmic visual acuity(logMAR).All of patients received intravitreal injection of conbercept(0.5mg，0.05ml)．Aftersurgery periodic review, best corrected visual acuity, intraocular pressure, slit lampmicroscope, fundus photography, OCT macular morphology was observed, and the meancentral retinal thickness of the macula (center retinal thickness, CRT) were measured.Afterone month of treatment if found still active CNV lesion or lesions or new lesions expand theline of injection therapy again.If they want to be treated again, before and after eachmonitoring vital signs, liver and kidney function, electrolyte, blood in urine routine, bloodcoagulation function, check the best corrected visual acuity, intraocular pressure, front mirrorunder slit lamp microscope, mydriatic fundus examination, eye B ultrasonic examination andfundus photography, application of OCT observation in the macular area retinal morphology,and the average central retinal thickness of macular area (center retinal thickness, CRT)measurements.Statistical analysis compared before and after treatment in patients withlog-MAR vision, CRT, paired f test, with P <0.05was considered statistically significant.Results:Treatment:After the first month of treatment a2PCV patients quit treatment, which takesone case of vitreous hemorrhage in patients with vitrectomy surgery, and1patienttreatment is not ideal with PDT treatment. BCVA:Before treatment36eyes BCVA of0.1to1.0, with an average of (0.79±0.58)logMAR.The first time a month later after treatment36eyes BCVA of0.1to1.0, the average on thevision of (0.69±0.29) logMAR, with the average for the first time on the vision beforetreatment (0.79±0.58) logMAR, the difference was statistically significant (t=2.48, P=0.018, P <0.05).Where visual acuity improved in10eyes, accounting for27.8%(10/36),vision unchanged in24eyes (66.7%)(24/36), decreased vision are two eyes5.5%(2/36).The first time two months later after treatment,34eyes of best corrected visual acuity of0.1to1.0, the average on the vision of (0.66±0.55) logMAR, compared with the meanlogMAR visual acuity before treatment, the difference was statistical significance (t=2.79,P=0.009, P <0.05).Where visual acuity improved in12eyes, accounting for35.3%(12/34),vision unchanged in18eyes (52.9%)(18/34), decreased vision were4eyes11.8%(4/34).CRT:Before treatment36eyes CRT is199~419um, average CRT was (300.94±30.66)um.The first time a month later after treatment36eyes CRT is151~406um, average (264.37±20.47) um,36.57um, the difference was statistically significant compared to the previoussurgery (t=2.89, P=0.019, P <0.05).The first time two months later after treatment34eyes CRT is149～418um, average(258．37±25．33) um,42.57um, the difference was statistically significant compared to theprevious surgery （t=2.32，P=0.041，P<0.05)；Complications:There are five times (four eyes, which appeared under the same eye twicea subconjunctival hemorrhage) injected eye troubles appear subconjunctival hemorrhage.Nohappens serious complications，such as uveitis，glaucoma，endophthalmitis，vitreoushemorrhage，retinal vascular obstruction，retinal detachment，etc.Conclusion:1. Intravitreal injection of conbercept effective short-term treatment of CNV,can stabilize or improve patients’ vision, no significant side effects.2.OCT can guide treatment by CRT value change, convenient clinical observation.3.Long-term efficacy remains a large multi-center, randomized, prospective study to assess.